Immutep Ltd · ASX:IMM
Immutep — Prima BioMed — Shareholder Meeting (April 2013)
14 slides from Immutep's shareholder meeting presentation, Apr 25, 2013
Slide 1: Orchestrating Cellular Therapy Clinical Trials Across 15 Countries
Exhibit 99.1 PRIMA Australian ASX/Media 24 PRESENTATION SYDNEY, will meeting Dr. accomplishments About ENDS develop cancer For USA Ms. +1 Australia +61 Europe Mr. +49 Prima Phone: ABN: www.primabiomed.com.au April (919) Gargosky Axel further James Jessica deliver (0) Investor/Media: BioMed 90 Prima
Slide 2: Outline
Orchestrating Dr. Chief Outline 4. 1. 2. 4.Blood 3. PRIMA 1 Background Introduction Ovarian Mucin Clinical CAN-004 Design Organogram CMO CANVAS Sharron Technical BIOMED Collection 1and Development cancer Gargosky update Autologous Duration Prima of Officer systems Centers and BioMed Prima accomplish
Slide 3: Why discuss clinical trials today / ovarian cancer unmet need
Orchestrating Why Today •Ovarian PRIMA 2 Clinical eCTD Interface Final Safety KoL Each Since ~80% Standard Unmet are in Iyear clinical ovarian of package will BIOMED impacts Cancer medical we trial trial data patients between of73,000 discussing discuss care will Autologous in integrity endpoints ca
Slide 4: Why Mucin 1 as a target for immunotherapy
Why •Mucin •It Nasopharyngeal •The Reference:Am •Mucin Differences fewer) PRIMA 3 Alteration Stimulation Mucin Up is to over mucin Target sugar 1a1BIOMED 1immunotherapy 40-fold isexpressed selected in a1Mucin chains. of cell found cellular the J the Clin 100% increase surface structure as 1? immune
Slide 5: CVac mechanism and Canvas clinical development overview
Manufacturing MNCs DCs The Mechanism Mucin Cvac T CVac Phase 1 (breast Oesophageal) 2 progressed 2/3 after PRIMA Canvas 4 CAN-001 CAN-002 CAN-003 CAN-003x cells CAN-004 DCs are 1st administered Overview activates Clinical Protocol 11-antigen (white separated target kill ovarian,fallopian BIOMED line
Slide 6: CAN-004 Randomized Double-Blinded Placebo-Controlled Trial of CVac
Outline 1. 2. 4. 3. evaluations CAN-004 A PRIMA Chemotherapy 5 Randomized, Background Introduction Ovarian Mucin Clinical CAN-004 Design Organogram CMO Blood CANVASBIOMED Collection 1and /Development cancer CANVAS update Duration Prima of Double-Blinded, systems Centers and BioMed accomplishments Pl
Slide 7: CAN-004 Organogram Overview
••Stage CAN-004 IWRS, CMOs Unblinded Leukapheresis Histopathology Immuno-specialty Radiology Global Reg. CRO UA, PRIMA 6 Will Screening 1:1 6800 Goal Started doses BY, Consultants randomization CRO dosed include –III/IV PM Scheduler, BIOMED compare Q1 US inProject (CANVAS) consultant DM CRO (~1000 4
Slide 8: Contract Manufacturing Organization (CMO) Selection
Contract (CMO) – •Comparability PRIMA 7 Achieved Training These This 3Selection Regional CMO Overseen Full consecutive, has scale oversight protocols were BIOMED manufacturing demonstrated selection comparability hands-on development selected Between successful and were review oftraining after accep
Slide 9: Vendor Qualification and Scaled Manufacturing
•Raw Qualification There clinical Legal Specific Training PRIMA 8 Vendor Country Scaled Planning Materials and issites, BIOMED aup Documentation –selection specific similarity contracts for clinical manufacturing Inspections –careful PSSVimport process specific, /inBudgets scale Clinical cellular –o
Slide 10: Blood Collection and Shipping Logistics
•We around •The MNC •Qualified •Linked ••Managed PRIMA 9 Established have logistics Collection Packaging the BIOMED interface implemented through the shipping globe amanagement successful global customized and Scheduling ofshipping under many and Shipping automated cold country temperate parties pac
Slide 11: Labeling
•We Labeling •Labels •Globally Final •Established •Qualified ••Linked •Managed PRIMA 10 Managed have Product are BIOMED interface developed accepted the shipping import generated also aShipping global customized integrated of and in under many region and from multiple customs country temperate packa
Slide 12: CANVAS Outline: Clinical Footprint
CANVAS Outline 4. 1. 2. 4.Blood 3. PRIMA 11 Background Introduction Ovarian Mucin Clinical CAN-004 Design Organogram CMO CANVASBIOMED Collection 1and Clinical clinical Development cancer update Duration Prima of systems sites Footprint Centers and BioMed Prima accomplishments Plan / Clinical offices
Slide 13: Accomplishments
•Globalized •Established ••Created Accomplishments •To •31 •Global •A •We PRIMA 12Demonstrated Established program approved date plandocumentation BIOMED we harmonized forwas have Manufacturing manufacturing Multi-center up courier and scale to established inspected active CAN-004 50relationships ba
Slide 14: Accomplishments and Thank You
Accomplishments •As IThank PRIMA 13 Approved would 30patients 743ofpatients clinical April you be BIOMED delighted for have 15 by centers consented your regulators been CAN-004 attention activated todosed to address in participate; 10bycountries your Primaquestions 32and patients (including allowed